Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a leading player in the biotechnology industry, is headquartered in the United States and focuses on developing innovative therapies for musculoskeletal health. Founded in 1983, Anika has achieved significant milestones, including the introduction of its proprietary hyaluronic acid-based products, which are designed to enhance joint health and improve patient outcomes. The company’s core offerings include viscosupplementation treatments and regenerative medicine solutions, setting it apart through its commitment to scientific excellence and patient-centric approaches. Anika Therapeutics has established a strong market position, recognised for its contributions to orthopaedics and sports medicine, and continues to expand its operational reach across major regions in North America and Europe. With a robust pipeline of products, Anika remains dedicated to advancing the field of therapeutic solutions for joint health.
DitchCarbon Score
How does Anika Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Anika Therapeutics, Inc.'s score of 23 is higher than 93% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Anika Therapeutics, Inc.'s reported carbon emissions
In 2023, Anika Therapeutics, Inc. reported total carbon emissions of approximately 3,679,000 kg CO2e, comprising 1,559,000 kg CO2e from Scope 1 emissions and 2,085,000 kg CO2e from Scope 2 emissions. This data reflects a consistent emissions profile compared to 2022, where the company reported identical figures for both scopes. Currently, Anika Therapeutics has not established any specific reduction targets or initiatives under the Science Based Targets initiative (SBTi) or other climate pledges. As a result, their climate commitments remain vague, with no documented plans for emissions reduction. The company operates within an industry increasingly focused on sustainability, highlighting the importance of developing robust climate strategies to align with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 1,559,000 | 0,000,000 |
| Scope 2 | 2,085,000 | 0,000,000 |
| Scope 3 | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Anika Therapeutics, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
